<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>Research in 2023 | ARSACS</title>
	<atom:link href="https://arsacs.com/fr/category/research-2023/feed/" rel="self" type="application/rss+xml" />
	<link>https://arsacs.com/fr</link>
	<description>Research That Heals</description>
	<lastBuildDate>Mon, 16 Mar 2026 22:16:04 +0000</lastBuildDate>
	<language>fr-CA</language>
	<sy:updateperiod>
	hourly	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	

<image>
	<url>https://arsacs.com/wp-content/uploads/2021/02/cropped-FAVICON-32x32.png</url>
	<title>Research in 2023 | ARSACS</title>
	<link>https://arsacs.com/fr</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>“Alterations of SACSIN RNA-binding properties are connected to the development of ARSACS”  &#8211; Dr.  Roberto Giambruno</title>
		<link>https://arsacs.com/fr/alterations-of-sacsin-rna-binding-properties-are-connected-to-the-development-of-arsacs-dr-roberto-giambruno-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 30 Mar 2024 22:00:31 +0000</pubDate>
				<category><![CDATA[Research in 2023]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=19994</guid>

					<description><![CDATA[Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurodegenerative disease mainly characterized by cerebellar ataxia, progressive spasticity and peripheral neuropathy. The disease is caused by mutations in the SACS gene (13q11) that alter the expression of the protein SACSIN. The first signs of the disease occur during childhood and the disease rapidly progresses over [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph"></p>


<div class="generic__paragraph" data-v-055796a9="">
<div data-v-055796a9="">
<div data-v-055796a9="">
<p>Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurodegenerative disease mainly characterized by cerebellar ataxia, progressive spasticity and peripheral neuropathy. The disease is caused by mutations in the SACS gene (13q11) that alter the expression of the protein SACSIN. The first signs of the disease occur during childhood and the disease rapidly progresses over the years. Currently, no treatment is available for ARSACS patients, mainly because the SACSIN molecular functions remain elusive. Unfortunately, this is a very challenging aspect caused by the gigantic dimensions of SACSIN that hampers the possibility of performing standard molecular biology experiments. <br />Curiously, many symptoms of ARSACS patients are common to patients affected by other neurodegenerative disorders. Thus, suggesting that these diseases may have common features also at the molecular level. Prompt by this observation, we extensively revised the literature and hypothesized that, similarly to other neurodegenerative disorders, the alteration of the SACSIN biological interactions is the main trigger of cell toxicity. We plan to demonstrate our hypothesis using an ARSACS cellular model, where we will study the connection between SACSIN altered interactions and cell death. Our study will pave the way to an innovative line of research aiming to restore SACSIN physiological interactions in order to prevent cell toxicity. Thus, having the possibility to impair the development and/or progression of the disease in ARSACS patients.</p>
</div>
</div>
</div>
<p><strong><em>T</em>he <a href="http://www.arsacsodv.it" target="_blank" rel="noopener">Organizzazione di volontariato (ODV)</a>, a volunteer organization in Italy founded by Mrs. Susanna Deluca and Dr. Paolo Arrigoni, a member of the Foundation’s Board, is funding this research project via the Fondazione Telethon an Italian non-profit organization which finances scientific research projects on rare diseases.</strong></p>
<p>Grant: 49.991€</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p><img decoding="async" class="alignnone size-full wp-image-20083 alignleft" src="https://arsacs.com/wp-content/uploads/2024/03/Roberto_Giambruno.-jpg.jpg" alt="" width="200" height="200" srcset="https://arsacs.com/wp-content/uploads/2024/03/Roberto_Giambruno.-jpg.jpg 200w, https://arsacs.com/wp-content/uploads/2024/03/Roberto_Giambruno.-jpg-150x150.jpg 150w" sizes="(max-width: 200px) 100vw, 200px" /></p>
<p>Dr. Roberto Giambruno</p>
<p style="text-align: left;">Consiglio Nazionale delle Ricerche -</p>
<p style="text-align: left;">CNR, Istituto per la Ricerca e l'Innovazione Biomedica (IRIB)</p>
<p>Palermo, Sicilia , Italy</p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Metabolic rewiring in cellular models of ARSACS”  &#8211; Dr. Paul Chapple</title>
		<link>https://arsacs.com/fr/metabolic-rewiring-in-cellular-models-of-arsacs-dr-paul-chapple-2-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sun, 21 Jan 2024 16:18:54 +0000</pubDate>
				<category><![CDATA[Research in 2023]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=19696</guid>

					<description><![CDATA[The viability of neurons in the brain depends on a complex series of interconnected biochemical reactions that constitute cellular metabolism. Disruption of these metabolic pathways is associated with neurological conditions, including Alzheimer’s and Parkinson’s. Recent technical advances in the analysis of cellular metabolites mean it is now possible to simultaneously quantify the levels and turnover [...]]]></description>
										<content:encoded><![CDATA[The viability of neurons in the brain depends on a complex series of interconnected biochemical reactions that constitute cellular metabolism. Disruption of these metabolic pathways is associated with neurological conditions, including Alzheimer’s and Parkinson’s. Recent technical advances in the analysis of cellular metabolites mean it is now possible to simultaneously quantify the levels and turnover of multiple metabolites in cells. We are using this technology to compare the metabolite profiles of control cells and cells that lack the protein sacsin, which is mutated in ARSACS. We believe disruption of cellular metabolism is likely to be particularly relevant to ARSACS. This is because it has previously been shown that the health of mitochondria, organelles where key metabolic enzymes are located, is reduced in cellular and animal models of ARSACS. Our goal is to define the metabolic changes that occur in sacsin deficient cells as we believe this will elucidate ARSACS disease mechanism and potentially identify targets for therapeutic intervention. Through this research we have identified disturbance in glutamate-glutamine metabolism in cells lacking sacsin. Glutamate is made from glutamine and these metabolites are important for brain function as glutamate can act as a neurotransmitter, carrying messages between neurons. Thus, a key current objective for the work is to mechanistically understand why glutamate-glutamine metabolism is altered and whether this is relevant for ARSACS.

Grant: £37,714

Duration: second  year of a 2 year project

Contact:
<p style="text-align: left;"><img loading="lazy" decoding="async" class="wp-image-17311  alignleft" src="https://arsacs.com/wp-content/uploads/2022/07/Paul_chapple_2022_-Research-report_website-150x150.jpg" alt="" width="165" height="165" /></p>
<p style="text-align: left;">Dr. Paul Chapple , Faculty of Medicine and Dentistry
Queen Mary University of London
London UL
<a href="mailto:j.p.chapple@qmul.ac.uk">j.p.chapple@qmul.ac.uk</a></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Therapeutic Approaches for ARSACS&#8221;- Drs. Benoit Gentil and Heather Durham</title>
		<link>https://arsacs.com/fr/therapeutic-approaches-for-arsacs-drs-benoit-gentil-and-heather-durham-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 09 Oct 2023 14:35:24 +0000</pubDate>
				<category><![CDATA[Research in 2023]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=19069</guid>

					<description><![CDATA[ARSACS is characterised by the lack of sacsin expression, and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies. Our strategy over the last years has been aimed at developing a replacement therapy, by peptide and/or gene vectors. The challenge of gene replacement therapies in ARSACS resides in the size [...]]]></description>
										<content:encoded><![CDATA[<p>ARSACS is characterised by the lack of sacsin expression, and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies. Our strategy over the last years has been aimed at developing a replacement therapy, by peptide and/or gene vectors. The challenge of gene replacement therapies in ARSACS resides in the size of the sacsin coding sequence which is not compatible with current vectors used for gene therapies. Using our expertise in sacsin domains functions, we have determined the best domain to be used for the resorption of molecular biomarker of the disease. Our laboratory is moving forward the development of replacement therapies focused on the development of peptide and gene therapies. We have generated a vector for gene therapy and are moving forward our project to determine its efficiency in modifying the course of ARSACS pathology in mice models. Our project at the preclinical stage also received support from NeuroSphere, the McGill platform dedicated to innovation and partnership in neuroscience research, through the IGNITE award ($50,000). This convergence of support from the Foundation and NeuroSphere will advance investigations into the development and feasibility of gene therapy for ARSACS.</p>
<p>Subvention : $100 000</p>
<p>Duration: First year of a 2 year project</p>
<p>Contacts<br /><img loading="lazy" decoding="async" class="alignleft  wp-image-3643" src="https://arsacs.com/wp-content/uploads/2021/02/Durham_Benoit_Nov_2017-150x150-2.jpg" alt="" width="199" height="199" /></p>
<p>Le Dr Benoit Gentil  et le Dr Heather Durham</p>
<p><span style="font-size: revert;">Département de kinésiologie et d'éducation physique, Université McGill </span></p>
<p>475 Pine Avenue West,   room 210,  Montreal (Québec)  H2W 1S4</p>
<p> heather.durham@mcgill.ca, <span style="font-size: revert;"> benoit.gentil@mcgill.ca</span></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Elucidating mechanisms underlying motor coordination rescue in a mouse model of ARSACS&#8221; &#8211; Drs. Alanna Watt &#038; Anne McKinney</title>
		<link>https://arsacs.com/fr/elucidating-mechanisms-underlying-motor-coordination-rescue-in-a-mouse-model-of-arsacs-drs-alanna-watt-anne-mckinney-3/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 09 Oct 2023 14:34:52 +0000</pubDate>
				<category><![CDATA[Research in 2023]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=19060</guid>

					<description><![CDATA[One of the hallmark features of ARSACS is dysfunction and eventual death of Purkinje cells in the cerebellum, which contributes to ataxia. Strikingly, not all Purkinje cells become ill and die: rather, specific patterns of vulnerability and resilience to cell death are observed in both human patients and mouse models of ARSACs. Our work focuses [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph"></p>


<p>One of the hallmark features of ARSACS is dysfunction and eventual death of Purkinje cells in the cerebellum, which contributes to ataxia. Strikingly, not all Purkinje cells become ill and die: rather, specific patterns of vulnerability and resilience to cell death are observed in both human patients and mouse models of ARSACs. Our work focuses on identification of the factors that promote resilience or prevent vulnerability to cell death. For example, we recently reported that both the location and molecular profile of Purkinje cells are involved in determining cell survival or death (Toscano-Marquez et al., 2021), and that a mitochondrial-targeted antioxidant can prevent ataxia worsening in mice (Toscano-Marquez et al., 2023). We continue this work focusing on (1) the identification of pathophysiological changes in the brain, including in both neurons and non-neuronal cells, as well as (2) identifying novel therapeutic targets.</p>
<p>Grant: $198,000</p>
<p style="text-align: left;">Duration: first  year of a 2 year project</p>
<p>Contact :<br /><img loading="lazy" decoding="async" class="wp-image-132 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/watt-1-150x150-2.jpg" alt="Dre Alanna Watt" width="198" height="198" /></p>
<p style="text-align: center;">Dr. Alanna Watt, <span style="font-size: 10.5pt; font-family: 'Open Sans',sans-serif; color: #666666;">Department of Biology</span></p>
<p style="text-align: center;">McGill University, Bellini Life Science  Building, room 265<br />3469 Sir William Osler, Montreal, Quebec Canada H3G 0B1 <br /><a href="mailto:alanna.watt@mcgill.ca"> alanna.watt@mcgill.ca</a></p>
<p style="text-align: center;"><img loading="lazy" decoding="async" class="wp-image-11142 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/Anne-McKinney-150x150-2.jpg" alt="" width="201" height="201" /></p>
<p style="text-align: center;">Dr. Anne McKinney, Department of Pharmacology and Therapeutics </p>
<p style="text-align: center;">McGill University Bellini Life Science Building, room 167<br />3469 Sir William Osler, Montreal, Quebec Canada H3G 0B1<br /><a href="mailto:anne.mckinney@mcgill.ca"> anne.mckinney@mcgill.ca</a></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“A mouse-human single nuclei-RNA seq profiling in ARSACS cerebellum: understanding how alterations in different cell types contribute to neurodegenration” &#8211; Dr. Francesca Maltecca</title>
		<link>https://arsacs.com/fr/a-mouse-human-single-nuclei-rna-seq-profiling-in-arsacs-cerebellum-understanding-how-alterations-in-different-cell-types-contribute-to-neurodegenration-dr-francesca-maltecca/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 09 Oct 2023 14:34:22 +0000</pubDate>
				<category><![CDATA[Research in 2023]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=19065</guid>

					<description><![CDATA[This project aims to evaluate the contribution of the different cerebellar cell types to neurodegeneration in ARSACS. In our recent publication (Del Bondio et al., 2023) we showed that in the ARSACS mouse cerebellum there is increased expression of astrocytic and microglial genes, supporting an inflammatory response taking place alongside the death of Purkinje cells (PCs), the most vulnerable and affected neurons in ARSACS [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph"></p>


<p>This project aims to evaluate the contribution of the different cerebellar cell types to neurodegeneration in ARSACS. In our recent publication (<em>Del Bondio et al., 2023</em>) we showed that in the ARSACS mouse cerebellum there is increased expression of astrocytic and microglial genes, supporting an inflammatory response taking place alongside the death of Purkinje cells (PCs), the most vulnerable and affected neurons in ARSACS patients and mouse models. In this project, we will employ single nuclei RNA sequencing (snRNAseq) in cerebellum, that can determine the expression level of genes within every isolated cell of the cerebellar tissue, providing the gene expression patterns specific to the different cell types in ARSACS. The analysis will be performed in the mouse model and in post-mortem ARSACS human cerebellum, and datasets compared.   Moreover, we will focus on the microglial profile of the human and mouse samples, to better investigate its role in disease progression. This human-mouse approach represents a promising opportunity to have a comprehensive view of ARSACS pathogenesis and to identify biomarkers of disease progression and novel potential targets for therapy.</p>
</p>
<p class="PANormalLevelIA" style="text-align: justify;">Subvention : $100 000</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p style="text-align: left;"><img loading="lazy" decoding="async" class="size-full wp-image-11103 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/DrFrancescaMaltecca-150x150-2.jpg" alt="" width="150" height="150" /></p>
<p>Dre Francesca Maltecca</p>
<p>Ospedale San Raffaele</p>
<p>Via Olgettina 60,20132, Milan, Italy  </p>
<p> <a href="mailto:maltecca.francesca@hsr.it">maltecca.francesca@hsr.it</a></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Discovery of new ARSACS modifier genes in the Saguenay founder population&#8221; &#8211; Dr. Simon Girard</title>
		<link>https://arsacs.com/fr/discovery-of-new-arsacs-modifier-genes-in-the-saguenay-founder-population-dr-simon-girard-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 09 Oct 2023 14:33:46 +0000</pubDate>
				<category><![CDATA[Research in 2023]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=19049</guid>

					<description><![CDATA[The Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay (ARSACS) is a rare and depilating neurological disease. It is found with much higher prevalences in several regions of the world, notably in Saguenay Lac St jean. This high prevalence is explained by a strong founder effect: in fact, more than 90% of ARSACS patients carry the [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">The Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay (ARSACS) is a rare and depilating neurological disease. It is found with much higher prevalences in several regions of the world, notably in Saguenay Lac St jean. This high prevalence is explained by a strong founder effect: in fact, more than 90% of ARSACS patients carry the same mutation which comes from a group of common ancestors. Despite this, the symptoms are not the same for everyone, which makes us think that other genetic factors could influence the progression of the disease. With a deep knowledge of each participant, we are able to link all ARSACS patients within a large family tree. Our project has three objectives: 1) analysis of the genome of ARSACS patients for whom we have a characterization detail clinical study,&nbsp; 2) complete genealogical reconstruction of ARSACS patients and their families and 3) linking of data to identify new regions of the genome linked to the disease. This study will allow us to better understand the genetic and cellular mechanisms that cause the disease and could eventually lead to new treatments to better help the patients and their families.</p>



<p class="wp-block-paragraph">Subvention : $100 000</p>



<p class="has-text-align-left wp-block-paragraph">Durée : un an</p>



<p class="wp-block-paragraph">Contact :</p>



<figure class="wp-block-image"><img loading="lazy" decoding="async" width="300" height="400" src="https://arsacs.com/wp-content/uploads/2023/10/Simon-Girard-.jpg" alt="" class="wp-image-19242" srcset="https://arsacs.com/wp-content/uploads/2023/10/Simon-Girard-.jpg 300w, https://arsacs.com/wp-content/uploads/2023/10/Simon-Girard--225x300.jpg 225w" sizes="(max-width: 300px) 100vw, 300px" /></figure>



<p class="wp-block-paragraph">Dr. Simon Girard, Professor &nbsp;</p>



<p class="wp-block-paragraph">Université du Québec à Chicoutimi</p>



<p class="wp-block-paragraph">555 boul.Université</p>



<p class="wp-block-paragraph">Chicoutimi (Québec) G7H 2G1</p>



<p class="wp-block-paragraph">simon2_girard@uqac.ca</p>



<div class="wp-block-group is-layout-constrained wp-block-group-is-layout-constrained">
<p class="has-text-align-center wp-block-paragraph">&nbsp;</p>
</div>











<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“ Détermination de la structure de la saccine ” – Dr Walid Houry</title>
		<link>https://arsacs.com/fr/structural-determination-of-sacsin-dr-walid-houry-2-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 09 Oct 2023 14:33:15 +0000</pubDate>
				<category><![CDATA[Research in 2023]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=19063</guid>

					<description><![CDATA[Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a progressive neurodegenerative genetic disorder characterized by an early childhood onset. ARSACS presents with polyneuropathy, with hallmark loss of cerebellar Purkinje neurons, and movement disorders featuring ataxia and spasticity. The etiology of ARSACS is attributed to one of more than 200 mutations in a protein-encoding gene called [...]]]></description>
										<content:encoded><![CDATA[<p>Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a progressive neurodegenerative genetic disorder characterized by an early childhood onset. ARSACS presents with polyneuropathy, with hallmark loss of cerebellar Purkinje neurons, and movement disorders featuring ataxia and spasticity. The etiology of ARSACS is attributed to one of more than 200 mutations in a protein-encoding gene called sacsin. These mutations result in mutated sacsin protein molecules with aberrant functions and clinical phenotypes. To identify or design drugs that can bind to and correct the sacsin protein pathologies, the structure and function of sacsin in both native (i.e., “healthy”) and mutated (i.e., “diseased”) states need to be elucidated. However, no research has yet been published on the purification of sacsin for <em>in vitro</em> and structural studies. This gap in research is not intentional but is due to the large size of sacsin (520 kDa), which has hindered determination of its structure and made basic biochemical and biophysical experiments problematic. Our laboratory aims to obtain atomic resolution structure of human sacsin. In this regard, we have now established reproducible methods to purify native sacsin, imaged sacsin in electron microscopic studies, and obtained preliminary 2D structural models. Obtaining high-resolution 3D structural data is our next goal.</p>
<p>Subvention : $100 000</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p><img loading="lazy" decoding="async" class="alignleft  wp-image-6572" src="https://arsacs.com/wp-content/uploads/2021/02/Walid_Houry_University_Toronto-e1606423339816.jpg" alt="" width="200" height="236" /></p>
<p>Dr. Walid A. Houry, Department of Biochemistry</p>
<p>Faculté de médecine Temerty de l'Université de Toronto<br />661 University Avenue,MaRS Centre, West Tower, Room 1612</p>
<p>Toronto, ON, Canada M5G 1M1</p>
<p> <a href="mailto:walid.houry@utoronto.ca">walid.houry@utoronto.ca</a></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Exploring and treating cognitive dysmetria in the mouse model of ARSACS&#8221; &#8211; Dr. Stefan Strack</title>
		<link>https://arsacs.com/fr/exploring-and-treating-cognitive-dysmetria-in-the-mouse-model-of-arsacs-dr-stefan-strack-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 09 Oct 2023 14:32:39 +0000</pubDate>
				<category><![CDATA[Research in 2023]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=19037</guid>

					<description><![CDATA[The cerebellum is critical for the coordination of movements and thought processes. Indeed, patient suffering from spinocerebellar ataxias including ARSACS commonly display psychiatric and cognitive symptoms. These cognitive and neuropsychiatric symptoms are often more debilitating than neurological symptoms and therefore deserve increased attention.  This researchexamines the time course of cognitive and motor dysfunction in the [...]]]></description>
										<content:encoded><![CDATA[<p>The cerebellum is critical for the coordination of movements and thought processes. Indeed, patient suffering from spinocerebellar ataxias including ARSACS commonly display psychiatric and cognitive symptoms. These cognitive and neuropsychiatric symptoms are often more debilitating than neurological symptoms and therefore deserve increased attention. </p>
<p>This researchexamines the time course of cognitive and motor dysfunction in the <em>Sacs</em> KO mouse model of ARSACS. The proposal is predicated on preliminary findings that short-term memory deficits precede motor deficits by at least three months. We will also explore whether small-molecule drugs currently in development for the treatment of Alzheimer’s disease rescue cognitive deficits in <em>Sacs</em> KO mice. Together with drugs that halt or delay degeneration of the cerebellum, we hope that these “cognitive enhancers” will improve quality of life of families afflicted with ARSACS and similar disorders.</p>
<p><strong> </strong></p>
<p>Subvention : $100 000</p>
<p style="text-align: left;">Durée : un an</p>
<p>Contact :</p>
<p><img decoding="async" class="alignleft" src="https://arsacs.com/wp-content/uploads/2023/09/Strack.jpg" /></p>
<p>Dr Stefan Strack, Département des neurosciences et de pharmacologie</p>
<p>Faculté de médecine Carver de l'Université de l'Iowa</p>
<p>2-452 BSB, 51 Newton Rd., Iowa City, IA 52242<br /><span class="gI"><span class="qu" tabindex="-1" role="gridcell" translate="no"><span class="go">stefan-strack@uiowa.edu</span></span></span></p>
<p style="text-align: center;"> </p>






<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>